Therapy Areas: Oncology
F1 Oncology plans acquisition of strategic CAR-T assets for treating solid tumour malignancies
14 November 2018 -

Biotechnology company F1 Oncology Inc said on Tuesday that it plans acquire all rights to novel chimeric antigen receptor T (CAR-T) cell therapy and manufacturing assets in Shanghai and Shenzhen for the development and commercialisation of cellular therapies in Greater China for the treatment of solid tumoor malignancies.

The acquisition will be initiated by the company's international affiliate, EXUMA Biotechnology Hong Kong, which has formed Shanghai EXUMA Biotechnology Co Ltd, a wholly foreign-owned enterprise (WFOE).

Under the agreement, Shanghai EXUMA will develop clinical programmes into multicentre trials under a centralised regulatory pathway based on the results of investigator-initiated trials (IITs) of CAR-T therapies for the treatment of metastatic renal cell carcinoma (mRCC) and other solid tumour malignancies.

In conjunction with the agreement, Shanghai EXUMA will be expanding its CAR-T cell processing capabilities at its new facility in the Shanghai International Medical Zone within Zhangjiang Innopark in Shanghai's Pudong district and its viral manufacturing capabilities at its newly constructed Shenzhen facility.

EXUMA Biotech integrates BioAtla's conditionally active biologic (CAB) protein therapeutic technology with F1 Oncology's proprietary CAR-T technologies to develop and commercialize CAB-CAR-T therapies and other ACTs for the treatment of solid tumour malignancies.

CAB-CAR-T cellular therapies are designed to be conditionally active only in the TME and may therefore help reduce potential adverse events associated with on-target, off-tumor effects of CAR-T therapies in solid tumours. F1 Oncology retains an exclusive global license to discover and develop CAB-based ACTs.

Login
Username:

Password: